Identification of and management approaches for the high-risk patient

Area of Science:

• Cardiovascular Medicine
• Pharmacology

Background:

• Atherothrombosis is a systemic vascular disease affecting coronary, cerebrovascular, and peripheral arteries.
• Multiple risk factors increase cardiovascular disease risk, even in asymptomatic individuals.
• Antiplatelet therapy is crucial for managing atherothrombotic disorders.

Purpose of the Study:

• To evaluate the efficacy of combination therapy (clopidogrel plus aspirin) versus aspirin monotherapy in patients with stable atherothrombosis.
• To determine if dual antiplatelet therapy improves outcomes in a large cohort of patients at high risk.

Main Methods:

• The Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management and Avoidance (CHARISMA) trial.
• A large-scale clinical trial involving over 15,000 patients with stable atherothrombosis.
• Comparison of clopidogrel plus aspirin versus aspirin plus placebo.

Main Results:

• The CHARISMA trial is ongoing, and results are pending.
• Expected to provide data on the comparative effectiveness of dual vs. single antiplatelet therapy.

Conclusions:

• Results from the CHARISMA trial will inform optimal management strategies for stable atherothrombosis.
• Findings will clarify the role of combination antiplatelet therapy in reducing cardiovascular events.